IBM Introduces Quantum Computing Platform on IBM Cloud
By apacciooutlook | Monday, December 03, 2018
YORKTOWN HEIGHTS, NY: IBM announces the general availability of quantum computing via the IBM Cloud. The cloud-enabled Quantum computing platform called IBM Quantum Experience, allows users to access and run experiments on IBM’s quantum processor.
IBM scientists have built a quantum processor that users can access on any desktop or mobile device by using IBM Cloud. The IBM Quantum Experience allows users to run algorithms and experiments on IBM’s quantum processor. It also allows users to work with quantum bits (qubits) and explore tutorials and simulations that unlock the infinite possibilities with quantum computing.
IBM believes quantum computing is the future of computing as it has the potential to solve certain problems that are impossible to solve on today’s supercomputers.
The quantum processor by IBM is composed of five superconducting qubits and is the leading approach towards building a universal quantum computer. A universal quantum computer has the capability to be programmed to execute any computing task and will be significantly faster than classical computers for a number of important applications for science and business.
Quantum computing works primarily differently from existing computers. A classical computer makes use of bits to process information, where each bit represents either a one or a zero. In contrast, a qubit can represent a one, a zero, or both at once, which is known as superposition. This property along withother quantum effects enables quantum computers to perform certain calculations immeasurably faster than is possible with classical computers.
With the assistance of software expertise from the IBM Research ecosystem, the IBM team has built a dynamic user interface on the IBM Cloud platform that allows users to easily connect to the quantum hardware via the cloud.
This advancement in quantum computing can lead to the discovery of new pharmaceutical drugs and completely safeguard cloud computing systems. It could also unlock new levels of artificial intelligence, develop new materials science to radically change industries, and search large volumes of big data.
“Quantum computers are very different from today’s computers, not only in what they look like and are made of, but more importantly in what they can do. Quantum computing is becoming a reality and it will extend computation far beyond what is imaginable with today’s computers,” says Arvind Krishna, senior vice president and director, IBM Research. “This moment represents the birth of quantum cloud computing. By giving hands-on access to IBM’s experimental quantum systems, the IBM Quantum Experience will make it easier for researchers and the scientific community to accelerate innovations in the quantum field, and help discover new applications for this technology.”
Bausch + Lomb and IBM Collaborate on Innovative App for Cataract Surgeons
IBM has also partnered with Bausch and Lomb to create a mobile application solution for cataract surgeons, to help them better streamline their workflow.
The app provides patient information and clinical insights, and intraocular lens (IOL) options on a single, digital platform at the point of care. The app is available for iPhone and iPad users. The services are hosted on Bluemix, IBM’s cloud platform.
“Bausch + Lomb is excited to collaborate with IBM to develop this innovative platform for ophthalmology,” says Andy Chang, senior vice president and general manager, U.S. Surgical, Bausch + Lomb. “By combining IBM’s advanced data management capabilities with Apple’s innovative app ecosystem and our clinical expertise, we are working to provide surgeons with a convenient, personalized tool that helps them better manage and access patient profiles digitally, and provide personalized IOL options. This unique relationship demonstrates Bausch + Lomb’s unwavering commitment to being a driving force in the ophthalmology industry by developing novel solutions that address the unmet needs of our customers and their patients.”